bluuebunny/crossref_metadata_2025_split huggingface dataset:
Toward equal participation: An auto-ethnography of facilitating consultations in the refugee sector
Authors: Elliot Sue 
Published: May 2016

This article uses an auto-ethnographic approach to exploring how one positions oneself as a facilitator in a layered and power-laden context in the refugee sector in New Zealand to ensure just and collaborative negotiations. It reflects on my facilitation practice based during a series of annual consultations between UNHCR, NGOs and refugee community representatives over a period of five years. The article begins by providing a brief overview of the New Zealand refugee system. This is followed by a review of relevant literature on the role of the facilitator and the role of facilitation within community development, an acknowledged field of social work. Reflections on facilitation practice within an ethnically diverse situation makes up the bulk of the article, which is written from the perspective of a Pakeha woman who has worked in the refugee sector for nearly 35 years, most recently in community development and capacity building of refugee-based organisations. This paper adopts a relatively descriptive style to a personal reflection on facilitating large consultations in the refugee sector in New Zealand. For ease of reading, the term refugee is used throughout, although the consultations focus on both refugee and asylum issues. As presented here, my reflexive analysis is interwoven with research and literature on facilitation and reflects who I am and what I value, in a myriad of tacit and overt ways. It focuses on the facilitation process and the role of the facilitator rather than on the outcomes of the consultations. I have deliberately focused on my own story as I consider this is the story I can ethically tell.
A review of a primary mental health service 10 years on
Authors: Taylor Sarah 
Published: May 2016

The past 10 years have seen a shift in mental health care in Aotearoa New Zealand towards early intervention and treatment at a primary care level providing a range of levels of mental health interventions in a variety of settings. Previously specialist mental health care had been the responsibility of community mental health teams and secondary service inpatient care which provided care for people with severe mental illness (3% of the population). In this article, I look at the move towards the provision of primary mental health care. I describe and review the Mental Health Brief Intervention Service in South Canterbury, one of the earliest primary mental health services initiated by the South Canterbury District Health Board, which started in 2005. I present research fi from my Master’s thesis Mental Health Brief Intervention – does it work? An evaluation of practice, and discuss how the Mental Health Brief Intervention Service has made a positive change for general practitioners, the client, the interface with other services including secondary mental health services and service delivery in general. Forms of consumer feedback are discussed along with the changes in the service over the last 10 years. It is written by myself, a social worker, who played an integral part in initiating and establishing the service and continues to have an active role as a clinician within the Mental Health Brief Intervention Service. This article is written to provide social workers with an overview of the establishment of the Mental Health Brief Intervention Service and the impact on service delivery. The role of the social worker is discussed as is the role of other health professionals within the team.
Chloroplast Genome Sequence of
Lagerstroemia guilinensis
(Lythraceae, Myrtales), a Species Endemic to the Guilin Limestone Area in Guangxi Province, China
Authors: Gu Cuihua , Tembrock Luke R. , Wu Zhiqiang 
Published: May 2016

ABSTRACT

We announce here the first complete chloroplast genome sequence of
Lagerstroemia guilinensis
(Lythraceae, Myrtales), a species endemic to the Guilin limestone area, along with its genome structure and functional gene annotations. The plant was collected from Guilin, Guangxi, China, and deposited as a germplasm accession of the Zhejiang Agriculture and Forestry University Collection (ZAFU 1507144). This genome will provide valuable information for future research of the
Lagerstroemia
genus and its relatives.
First Insights into the Draft Genome of Clostridium colicanis DSM 13634, Isolated from Canine Feces
Authors: Poehlein Anja , Schilling Tobias , Bhaskar Sathya Narayanan Udhaya , Daniel Rolf 
Published: May 2016

ABSTRACT

Clostridium colicanis
DSM 13634 is a strictly anaerobic, rod-shaped, and spore-forming bacterium. It produces acids from common sugars such as glucose and fructose. The draft genome consists of one chromosome (2.6 Mbp) and contains 2,159 predicted protein-encoding genes.
Draft Genome Sequence of an Oxalate-Degrading Strain of Clostridium sporogenes from the Gastrointestinal Tract of the White-Throated Woodrat (
Neotoma albigula
)
Authors: Oakeson Kelly F. , Miller Aaron , Dale Colin , Dearing Denise 
Published: May 2016

ABSTRACT

The gastrointestinal tract of the white-throated woodrat
Neotoma albigula
harbors a diverse microbial population that functions in the degradation of ingested plant secondary compounds. Here, we present the draft genome sequence and annotation of
Clostridium sporogenes
strain 8-O, a novel oxalate-degrading bacterium isolated from the feces of
N. albigula
.
Draft Genome Sequence of
Flavihumibacter
sp. Strain CACIAM 22H1, a Heterotrophic Bacterium Associated with Cyanobacteria
Authors: Moraes Pablo Henrique Gonçalves , Lima Alex Ranieri Jerônimo , Siqueira Andrei Santos , Dall'Agnol Leonardo Teixeira , Baraúna Anna Rafaella Ferreira , Aguiar Délia Cristina Figueira , Fuzii Hellen Thais , Albuquerque Keila Cristina Ferreira , de Lima Clayton Pereira Silva , Nunes Márcio Roberto Teixeira , Vianez-Júnior João Lídio Silva Gonçalves , Gonçalves Evonnildo Costa 
Published: May 2016

ABSTRACT

Here, we present a draft genome and annotation of
Flavihumibacter
sp. CACIAM 22H1, isolated from Bolonha Lake, Brazil, which will provide further insight into the production of substances of biotechnological interest.
Draft Genome Sequence of an Aldoxime Degrader,
Rhodococcus
sp. Strain YH3-3
Authors: Yamaguchi Takuya , Asano Yasuhisa 
Published: May 2016

ABSTRACT

Rhodococcus
sp. strain YH3-3 has been isolated as an (
E
)-pyridine-3-aldoxime degrader. Here, we report the draft genome sequence of this strain, with a size of 7,316,908 bp, average G+C content of 62.15%, and 7,281 predicted protein-coding sequences.
Oral Hygiene and Risk of Nasopharyngeal Carcinoma—A Population-Based Case–Control Study in China
Authors: Liu Zhiwei , Chang Ellen T. , Liu Qing , Cai Yonglin , Zhang Zhe , Chen Guomin , Xie Shang-Hang , Cao Su-Mei , Shao Jian-Yong , Jia Wei-Hua , Zheng Yuming , Liao Jian , Chen Yufeng , Ernberg Ingemar , Vaughan Thomas L. , Adami Hans-Olov , Huang Guangwu , Zeng Yi , Zeng Yi-Xin , Ye Weimin 
Published: May 2016

Abstract
Background: The association between oral health and risk of nasopharyngeal carcinoma (NPC) is largely unknown. Further understanding could shed light on potential pathogenic mechanisms and preventive measures.
Methods: We conducted a population-based case–control study in southern China between 2010 and 2014. We enrolled 2,528 incident NPC cases, aged 20–74 years, and 2,596 controls, randomly selected from the total population registers, with frequency matching to the 5-year age and sex distribution of the cases by geographic region. We interviewed subjects using a structured questionnaire inquiring about oral health indicators and potential confounding factors. We used unconditional logistic regression to estimate multivariate-adjusted ORs with 95% confidence intervals (CI).
Results: A higher number of filled teeth was associated with an elevated risk of NPC. Individuals with 1 to 3 and more than 3 teeth filled versus none had adjusted ORs of 1.25 (95% CI, 1.06–1.49) and 1.55 (95% CI, 1.13–2.12), respectively (Ptrend = 0.002). Conversely, the adjusted OR for those who brushed teeth twice or more per day versus once or less per day was 0.62 (95% CI, 0.55–0.70). We detected a borderline significant positive association with earlier age at first adult tooth loss.
Conclusion: Our study suggested a positive association between some indicators of poor oral health and risk of NPC. Further studies are needed to confirm whether the findings are causal and, if so, to further explain the underlying mechanisms.
Impact: Improvement of oral hygiene might contribute to reducing NPC risk. Cancer Epidemiol Biomarkers Prev; 25(8); 1201–7. ©2016 AACR.
Abstract A115: A novel therapy targeting Wnt receptor in metastatic solid tumors
Authors: Gujral Taran , Kirschner Marc 
Published: May 2016

Abstract
Metastasis is responsible for as much as 90% of cancer-associated mortality; yet progress has remained slow in developing effective drugs either specifically targeting metastasis or targeting cells with metastatic potential. To date, surgical resection is considered the best treatment for most cancers; however, it provides limited benefit in metastatic cancers. Although there are numerous studies showing the migratory potential of metastatic cells and relating metastasis to the biology of the epithelial-mesenchymal transition (EMT), little is known about how tumor cells engage this fundamental cellular program. We have recently discovered a new non-canonical Wnt pathway through Wnt5-Fzd2 that drives EMT, cellular migration, invasion in vitro and tumor growth and metastasis in vivo. Using focused proteomics approaches, we have identified several novel signaling proteins downstream of Fzd2, including Fyn, Stat3, Mek-Erk-S6k, and Pyk2 kinase. Our new findings highlight critical nodes in the Fzd2 pathway that are linked to metastatic phenotypes such as increased motility, and EMT. Overall, these findings establish the driver role of Fzd2 signaling in diverse solid tumors and make Fzd2 a potential first-in-class therapeutic target for metastatic cancers.
Citation Format: Taran Gujral, Marc Kirschner. A novel therapy targeting Wnt receptor in metastatic solid tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A115.
Abstract A139: Targeting cholesterol with beta-cyclodextrins disrupt PI3K-AKT, sensitizing cancer cells for chemotherapeutics
Authors: Yamaguchi Ryuji 
Published: May 2016

Abstract
Activated PI3K-AKT pro-survival signal is the major obstacle to successful chemotherapies. Activated growth-factors receptors such as EGFR and IGF1R generate two signal transduction cascades; RTK-Ras-MAPK cascades generating proliferation signals, and RTK-PI3K-AKT cascades generating pro-survival signals that enhance glucose-uptake and stimulate energy production at mitochondria and at the same time, protecting mitochondria from mitochondria-dependent apoptotic signals. When we depleted cholesterol from plasma membranes with beta-cyclodextrins (beta-CDs) in tissue culture cells, we found that RTKs were activated normally in the absence of cholesterol, and activating Ras-MAPK pathways. However, beta-CD disrupted the signal transduction between PI3K and AKT, attenuating PI3K-AKT pro-survival signal in cancer cells and sensitizing them for mitochondria-dependent apoptosis. Injected into mice, beta-CD blocked IGF1-induced hypoglycemia in 5-hour starved mice, suggesting that the IGF1R-PI3K-AKT pathway was disrupted. Injected into mice carrying human cancer cells, it enhanced the efficacies of chemotherapeutics that could trigger mitochondria-dependent apoptosis quickly such as the combination of 2-dexoyglucose and Bcl2 antagonists or TNF-related apoptosis-inducing ligand (TRAIL).
Citation Format: Ryuji Yamaguchi. Targeting cholesterol with beta-cyclodextrins disrupt PI3K-AKT, sensitizing cancer cells for chemotherapeutics. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A139.
Abstract A142: The effect of beta2-glycoprotein I on anti-tumor cell migration
Authors: Chiang An-Na , Li Wan-Chun , Yeh Shu-Hau , Cheng Shu-Wei , Lin Yu-Shan 
Published: May 2016

Abstract
β2-glycoprotein I (β2-GPI) is a multifaceted protein with diverse biological functions, including triglyceride metabolism, blood coagulation and homeostasis. We previously reported that β2-GPI exhibits significant anti-migration effect on human aortic endothelial cells through the NF-κB/eNOS/NO signalling pathway. Migration of endothelial cells has known to be involved in vascular physiology and pathology, such as angiogenesis and tumorigenesis. We thus hypothesize that β2-GPI may also play a critical role in the regulation of tumor cell migration and invasion. Human plasma protein was precipitated by 3% (v/v) perchloric acid and β2-GPI was purified by heparin-Sepharose affinity chromatography. The purity of β2-GPI was determined by SDS/PAGE and Western blot analysis. The influence of β2-GPI on tumor cell migration was analyzed by wound healing and trans-well migration analysis. Using wound healing assay, we found that purified β2-GPI was able to inhibit cell migration in various tumor cancers, such as A375 human melanoma cancer cells, B16-F10 mouse melanoma cells, oral squamous cell carcinoma (OSCC)-derived cell line human tongue squamous carcinoma (SAS), and human head neck squamous cell carcinoma (HNSCC) cell lines FaDu (hypopharyngeal) carcinoma. In the trans-well assay, β2-GPI also showed markedly inhibition of tumor cell migration from the upper chamber to the lower chamber. Furthermore, β2-GPI revealed dose-dependently anti-invasion effect on melanoma cancer cells. The findings of the present study provide insight into the ability of β2-GPI to inhibit tumor cell migration, which indicates a novel direction for its application in anti-cancer therapy.
Citation Format: An-Na Chiang, Wan-Chun Li, Shu-Hau Yeh, Shu-Wei Cheng, Yu-Shan Lin. The effect of beta2-glycoprotein I on anti-tumor cell migration. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A142.
Abstract A148: Developing a baculovirus expression system to evaluate the role of B2-glycoprotein I in anti-tumor cell growth
Authors: Lin Yu-Shan , Leu Shr-Jeng , Chiang An-Na 
Published: May 2016

Abstract
β2-glycoprotein I (β2-GPI) is a human plasma protein which has been reported to elicit an anti-cell migration effect on human aortic endothelial cells in our previous study. Migration of endothelial cells has been found to be involved in tumorigenesis, however, whether β2-GPI regulates tumor cell growth is unknown. In this study, we investigated the biological effect of β2-GPI on anti-cell migration and proliferation in tumor cells using a baculovirus expression system. Based on Bac-to-Bac Baculovirus Expression system, the cDNA encoding B2-GPI gene has been constructed and cloned into the pFastBac vector with additionally designed sequences, including a Honeybee Melittin Secretion Signal, a dual Flag/StrepII affinity tag and a Tabacco Etch Virus cleavage site at N terminal end and a C-terminal IgG1 Fc fusion protein sequences. This recombinant bacmid DNA containing a complete B2-GPI gene was transfected into insect Sf9 cells to generate recombinant baculovirus. Expression of these chimeric proteins in insect cells resulted in efficient assembly and release of hybrid recombinant B2-GPI protein into cultured media. The fusion proteins containing IgG1-Fc sequences can be purified by the protein A affinity column. Finally, we collected the recombinant B2-GPI in high purity and expression yield. Direct administration of recombinant B2-GPI protein resulted in an effective inhibition of the melanoma cell migration and tumor growth. Development of this baculoviral-based system provides an option for investigation in the anti-tumor cell growth function of B2-GPI in vitro and in vivo. Our study provides a baculoviral-based approach which opens a new perspective for developing B2-GPI as an agent in anti-cancer therapy.
Citation Format: Yu-Shan Lin, Shr-Jeng Leu, An-Na Chiang. Developing a baculovirus expression system to evaluate the role of B2-glycoprotein I in anti-tumor cell growth. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A148.
Abstract A19: Network analysis of gene essentiality in CRISPR screens
Authors: Jiang Peng , Liu Xiaole Shirley 
Published: May 2016

Abstract
CRISPR screen is a powerful technique to study gene essentiality at genome scale. Based on our analysis of public CRISPR screen data, the essential genes selected in CRISPR screens can be predicted by the expression level of their neighboring genes in the protein interaction network. Meanwhile, the quality of CRISPR screen results can be significantly enhanced through network neighbor information. Through analysis of tumor-profiling data, we found the network neighbor expression to be a significantly better predictor of survival than gene expression alone. Thus, our study provides a reliable method for CRISPR screen analysis and gene essentiality study. The source code and web application of our method is available at http://nest.dfci.harvard.edu.
Citation Format: Peng Jiang, Xiaole Shirley Liu. Network analysis of gene essentiality in CRISPR screens. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A19.
Abstract A196: Stromal cells suppress cancer development by secreted GAPDH-E-cadherin interaction
Authors: Manabu Kawada , Yoshida Junjiro , Inoue Hiroyuki , Ohba Shun-ichi , Yamasaki Manabu , Usami Ihomi , Sakamoto Shuichi , Abe Hikaru , Watanabe Takumi , Nomoto Akio , Shibasaki Masakatsu 
Published: May 2016

Abstract
The cancer tissue contains lots of stromal cells. Among them, fibroblast-like stromal cells regulate the growth of cancer cells positively and negatively through secreted factors and adhesion. We have been studying the interactions between cancer cells and stromal cells using small molecules that can modulate the interactions. We previously reported that gastric stromal cells enhance the growth of gastric cancer cells through secretion of IL-6, which is stimulated by gastric cancer cells through PGE2 and TNF-alpha reciprocally. Here we report that GAPDH, a house keeping protein, is a negative regulator of the interactions. By purifying the growth inhibitory activity against gastric cancer cells from secreted factors of gastric stromal cell we unexpectedly identified GAPDH as an active substance. While GAPDH is known to be secreted extracellularly, its growth inhibitory activity has not yet. As a result, GAPDH is found to be secreted from various organ-derived stromal cells and to inhibit the growth of various cancer cell lines. We have found that this growth inhibitory activity of GAPDH doesn't need its original enzymatic activity and GAPDH inhibits mTOR-p70S6 kinase pathway by binding to E-cadherin on cancer cell membranes. We propose that negative regulation of cancer growth using GAPDH could be a new anti-cancer strategy.
Citation Format: Kawada Manabu, Junjiro Yoshida, Hiroyuki Inoue, Shun-ichi Ohba, Manabu Yamasaki, Ihomi Usami, Shuichi Sakamoto, Hikaru Abe, Takumi Watanabe, Akio Nomoto, Masakatsu Shibasaki. Stromal cells suppress cancer development by secreted GAPDH-E-cadherin interaction. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A196.
Abstract A32: Accelerating biomarker discovery for companion diagnostics through mouse trials with PDX models in clinical settings
Authors: Jiang Jingjing , Yu Tengfei , Yan Ying , Du Wei , Tang Tingting , Yang Xuqin , Gu Jiali , Hua Liang , Ye Xin Katherine , Gu Zhenyu 
Published: May 2016

Abstract
Companion diagnostics are assays intended to find the right drug for the right patient in targeted cancer therapy. Biomarker discovery is the first step in companion diagnostics development. Currently great efforts have been devoted to biomarker discovery and validation through analysis of clinical samples. However, the quantity and quality of tumor samples from drug candidate treated patients are very limited during drug development, which has posed challenges for fast and cost-effective drug-diagnostic co-development.
Patient derived xenograft (PDX) tumor models have been demonstrated to represent cancer complexity and heterogeneity known in patients. Drug targets and responses to targeted drugs in PDX models show high correlation to those in cancer patients.
We have established over 950 PDX tumor models and around 100 resistance models to drugs of interest. To evaluate mouse trials with PDX models as biomarker discovery platform, we have been testing PDX models with SOCs and clinical drug candidates such as targeted inhibitors against FGFRs, c-Met/ALK, HER2, EGFR, cell cycle regulators, Ras/Raf pathway, PI3K/Akt pathway, as well as chemotherapy drugs in a biomarker-driven multi-drug multi-arm clinical trial setting, and have accumulated more than 1500 data sets and associated PD samples. Through analysis of drug response data and genomic profile data from PDX models, we show that many of the drug sensitivity biomarkers and drug resistance biomarkers identified in clinical studies can be faithfully found in PDX studies. Moreover, some novel predictive biomarkers for candidate drugs in relatively early clinical stage have also been identified and will be further validated in future clinical studies.
The availability of a large number of PDX models, the flexibility of designing studies and the quickness in testing new drug candidates make this type of mouse trial and its derived data sets a useful platform for biomarker discovery in companion diagnostics development.
Citation Format: Jingjing Jiang, Tengfei Yu, Ying Yan, Wei Du, Tingting Tang, Xuqin Yang, Jiali Gu, Liang Hua, Xin Katherine Ye, Zhenyu Gu. Accelerating biomarker discovery for companion diagnostics through mouse trials with PDX models in clinical settings. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A32.